Vitamin D Deficiency and Insufficiency in HIV-infected Children and Young Adults

Meyzer, Candice; Frange, Pierre; Chappuy, Hélène; Desse, Blandine; Veber, Florence; Clésiau, H. Le; Friedlander, Gérard; Blanche, Stéphane; Souberbielle, Jean‐Claude; Tréluyer, Jean‐Marc; Courbebaisse, Marie

doi:10.1097/inf.0b013e3182a735ed

Cited by 24 publications

(15 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interactions with HIV serostatus were explored and none were found to be significant in adjusted models, with the exception of the effect of 25[OH]D on 1, 25[OH] 2 D as described below. The vitamin D deficiency prevalence of 41% observed among HIV-infected men in this sample of MACS lies in the middle of a very wide range of prevalence estimates (10%-83%) reported in other studies of HIV-infected individuals 16,20,[35][36][37] and is consistent with the 39% prevalence reported in the general population. 16 The wide range of vitamin D deficiency prevalence estimates in HIV infected likely results from differences in demographics, geographic location, seasonality, and other study population characteristics as well as varying definitions of vitamin D deficiency.…”

Section: Determinants Of 25[oh]d Statussupporting

confidence: 76%

Vitamin D Deficiency and Metabolism in HIV-Infected and HIV-Uninfected Men in the Multicenter AIDS Cohort Study

Zhang

Tin

Brown

et al. 2017

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

Section: Determinants Of 25[oh]d Statussupporting

confidence: 76%

Vitamin D Deficiency and Metabolism in HIV-Infected and HIV-Uninfected Men in the Multicenter AIDS Cohort Study

Zhang

Tin

Brown

et al. 2017

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

“…Subjects receiving tenofovir did not differ at baseline or in the change in 25 In a few studies evaluating children and young adults with HIV infection, researchers found a high prevalence of suboptimal 25(OH)D, ranging from 71% to 89% <30 ng/mL [3,[26][27][28]] to 33% to 78% <20 ng/mL [1,4,[29][30][31], with 1 group reporting 87% <15 ng/mL [2]. Our results support the finding that suboptimal 25(OH)D status is common in unsupplemented youth, with 95% at baseline having a 25(OH)D <32 ng/mL.…”

Section: Resultsmentioning

confidence: 99%

Safety and Efficacy of High-Dose Daily Vitamin D3 Supplementation in Children and Young Adults Infected With Human Immunodeficiency Virus

Dougherty

Schall

Zemel

et al. 2014

Journal of the Pediatric Infectious Diseases Society

View full text Add to dashboard Cite

Background. Suboptimal vitamin D (vitD) status is common in children and young adults infected with human immunodeficiency virus (HIV). The vitD supplemental dose needed to normalize vitD status in this population is unknown. Methods. In this double-blind trial, subjects infected with HIV ages 8.3 to 24.9 years were randomized to vitD 3 supplementation of 4000 IU/day or 7000 IU/day and evaluated at 6 and 12 week for changes in vitD status and HIV indicators. A dose was considered unsafe if serum calcium was elevated (above age and sex-specific range) associated with elevated serum 25 hydroxyvitamin D (25(OH)D); >160 ng/mL). Results. At baseline, 95% of subjects (n = 44; 43% with perinatally acquired HIV, 57% with behaviorally acquired HIV) had a suboptimal serum 25(OH)D concentration of <32 ng/mL (mean ± standard deviation, 19.3 ± 7.4; range, 4.4-33.6 ng/mL). After 12 weeks (main outcome) of D 3 supplementation, both D 3 doses were safe and well tolerated, with no evidence of elevation of serum calcium concentrations or deterioration in HIV immunologic or virologic status. Sufficient vitD status, defined as serum 25(OH)D 32 ng/mL, was achieved in 81% of all subjects, and only the 7000 IU/day group (86%) achieved this a priori efficacy criterion in >80% of subjects. Change in serum 25(OH)D did not differ between HIV acquisition groups. Conclusions. A 7000 IU/day D 3 supplementation was safe and effective in children and young adults infected with HIV.

show abstract

“…Vitamin D status may be more important to characterize in HIV-infected children/youth, as peak bone mass is not attained until age 25. The prevalence of 25(OH)D < 30 ng/mL in perinatally-infected children and young adults on ART was 43% in Thailand(27*), but reported in 96% in a Parisian cohort(28). In the US, 87% of behaviorally-infected(1) and 56% of perinatally-infected(29) children and young adults had 25(OH)D < 15 ng/mL.…”

Section: Vitamin D Deficiency In Hivmentioning

confidence: 99%

Vitamin D and bone loss in HIV

Hileman

Overton

McComsey³

2016

Current Opinion in HIV and AIDS

View full text Add to dashboard Cite

Purpose of review Bone health has become an increasingly important aspect of the care of HIV-infected patients as bone loss with antiretroviral therapy (ART) initiation is significant and osteopenia and osteoporosis are highly prevalent. Vitamin D is tightly linked to calcium balance and bone health and vitamin D deficiency is common in HIV. This review outlines the epidemiology of vitamin D deficiency in HIV, summarizes our current understanding of the relationship between vitamin D and bone loss in HIV and the impact of vitamin D supplementation in this patient group. Recent findings While data are conflicting as to whether vitamin D deficiency is more prevalent among HIV-infected individuals than in the general population, there are several reasons for why this patient group may be at heightened risk. Studies linking vitamin D deficiency to bone loss in HIV are limited; however, data from randomized clinical trials suggest a benefit of vitamin D supplementation for the prevention of bone loss with ART initiation and for the treatment of bone loss with bisphosphonate therapy. Summary There are too limited data to recommend universal screening of vitamin D status or supplementation to all HIV-infected individuals. However, testing 25-hydroxyvitamin D levels in those at risk for deficiency and treating patients found to be deficient or initiating antiretroviral therapy or bisphosphonate therapy should be considered. Further study on vitamin D supplementation is needed regarding the potential benefit on immune activation and restoration in this patient group.

show abstract

Vitamin D Deficiency and Insufficiency in HIV-infected Children and Young Adults

Abstract: VDD and VDI were common in both HIV-infected and control groups, and serum 25(OH)D concentrations were significantly lower in controls than in HIV-infected children.

Cited by 24 publications

References 34 publications

Vitamin D Deficiency and Metabolism in HIV-Infected and HIV-Uninfected Men in the Multicenter AIDS Cohort Study

Vitamin D Deficiency and Metabolism in HIV-Infected and HIV-Uninfected Men in the Multicenter AIDS Cohort Study

Safety and Efficacy of High-Dose Daily Vitamin D3 Supplementation in Children and Young Adults Infected With Human Immunodeficiency Virus

Vitamin D and bone loss in HIV

Contact Info

Product

Resources

About